Augmenix's Acquisition

Augmenix was acquired by Boston Scientific Corporation on September 06, 2018.

Augmenix is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Augmenix's initial product wi…

Articles about Augmenix's Acquisition: